|
T.ONC
|
Unfortunately, we won't know till they tell us in a couple of months. And...
|
|
T.ONC
|
Here's a nice company for comparison... On January 2, 2022...
|
|
T.ONC
|
Today's volume strongly suggests that ONC is diluting big-time through...
|
|
T.ONC
|
Okay, this is a big deal. There is tons of informaiton out there re this...
|
|
T.ONC
|
Based on today's trading, it would appear that at least one person knows...
|
|
T.ONC
|
Darn, slides 3 and 4 look much less like a homerun once I see them clearly...
|
|
T.ONC
|
That fourth slide is very interesting. Though barely legible, this is...
|
|
T.ONC
|
The SP is going to drop by at least 25% if ONC fails to deliver updated...
|
|
T.ONC
|
I beileve that if the data are strong (as strongly hinted at by MC) then ONC...
|
|
T.ONC
|
Mayl 2017: ONC announced results from IND.213 and were granted FDA Fast...
|
|
T.ONC
|
Sometime between February and May this year, Advisor Group acquired 238,000...
|
|
T.ONC
|
Slight correction. I said CELTIL when I meant CTC (Cirucluating Tumour...
|
|
T.ONC
|
These results from Bracelet (yet to be updated to May but almost certain to...
|
|
T.ONC
|
This drug was approved by the FDA on Feb 3, 2023. https://www.esmo.org...
|
|
T.ONC
|
It is begining to feel like Pelareorep should be standard of care for BC and...
|
|
T.ONC
|
Fyi https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770247
|
|
T.ONC
|
Found this and it suggests the PFS and DCR may be of more interest that ORR...
|
|
T.ONC
|
Thanks everyone for their thoughts re this data set. Geneman... what...
|
|
T.ONC
|
First glance.. the six month PFS rate is very eye-catching. Numbers...
|
|
T.ONC
|
Just about to blow past the one and two year highs. Nice. I'm...
|